Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, open-label, uncontrolled study in patients with cancer cachexia

X
Trial Profile

A Multicenter, open-label, uncontrolled study in patients with cancer cachexia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Cachexia
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 10 May 2022 Planned End Date changed from 1 Aug 2018 to 31 Aug 2018.
    • 22 Jan 2021 According to an ONO Pharmaceutical media release, based on the results of ONO-7643-04 and ONO-7643-05 studies, the company has received the manufacturing and marketing approval of Adlumiz (anamorelin hydrochloride) Tablet 50mg (Adlumiz), for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan.
    • 15 Aug 2019 Status changed to completed as per results published in the Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top